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Abstract
Background: Resurgence of pertussis in the post-vaccination era has been reported in Western countries. A shift
of cases from school-age children to adolescents, adults and children under 1 year of age has been described in
the last decade, and mortality rates in infants are still sustained. We aimed to review and discuss the possible
vaccination strategies which can be adopted in order to improve the pertussis control, by searches of Pubmed,
and websites of US and European Centers for Disease Control and Prevention, between 1st January 2002, and
1st March 2013.
Discussion: The following vaccination strategies have been retrieved and analysed: the cocooning strategy, the
immunization of pregnant women and newborns, vaccination programs for preschool children, adolescents,
adults and health-care workers. Cost-effectiveness studies provide some contrasting data, mainly supporting
both maternal vaccination and cocooning. Adolescent and/or adult vaccination seems to be cost-effective,
however data from observational studies suggest that this vaccination strategy, used alone, leads to a reduced
pertussis burden globally, but does not affect the disease incidence in infants. Moreover, substantial logistical
and economic difficulties have to be overcome to vaccinate the largest number of individuals.
Summary: The simultaneous use of more than one strategy, including cocooning strategy plus vaccination of
adolescents and adults, seems to be the most reasonable preventive measure. The development of new
highly immunogenic and efficacious pertussis vaccines continues to be a primary objective for the control of
pertussis.
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Background
Pertussis is still a major public health concern in West-
ern countries where, despite high vaccination coverage,
yearly incidence continues to increase and mortality in
children under 6 months of age reaches 0.2% [1]. This
trend has been reported in Canada, the United States
and Australia since the 1980s and in Europe some years
later [2]. Large outbreaks recently occurred in the
United States, reporting impressive figures. As an ex-
ample, during the 2010 Californian epidemic, over 9,000
cases have been recorded, for a rate of 23.4 per 100,000,
the highest number in 60 years [3-5]. Similarly, in the
UK in 2012 the highest mortality rate was registered
since 1982, with 10 deaths, all occurred in infants under
12 months old [6]. In Europe, 27 countries currently
provide national surveillance data for pertussis under
vaccine-preventable diseases): 17,596 confirmed cases
were reported in 2009, corresponding to an incidence of
4.9 per 100,000 [7]. Data were heterogeneous among
countries, ranging from 0.02 to 115 per 100,000. Pertus-
sis rates were higher in Northern European countries,
probably because some of them, including Sweden,
Norway and Germany, achieved a high immunization
coverage and introduced a booster dose after a primary
immunization only recently. However, different rates
may have been influenced not only by differences in vac-
cination policies, but also by differences in reporting
procedures and surveillance systems, case definitions,
and laboratory methods [2,7,8].
Possible reasons for the re-emergence of pertussis include
the increased awareness of the disease, the development of
new clinical definitions, and the spread use of polymerase
chain reaction assays for laboratory confirmation, improv-
ing the diagnostic ability even in cases with atypical presen-
tation [3,4,7,9]. Genetic changes in circulating strains of* Correspondence: maurizio.demartino@unifi.it
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Bordetella pertussis, occurring under selective vaccination
pressure, should also be considered [4,10]. Finally, protec-
tion from pertussis is not life-long, but restricted to a
period of 5–8 years, after natural infection, as well as after
vaccination [11]. This waning of immunity explains the
shift of the incidence peak from school-age to adolescents/
adults, and the spread from these subjects to infants and
young children, still unvaccinated or not-fully vaccinated
(Figure 1) [4,7,8,12-17]. Children under 6 months of age
have a 20-fold higher rate of infection than the total popula-
tion and ≥ 90% of pertussis deaths occur in this age class
[18]. Aim of the present study is to review and discuss the
possible vaccination strategies which can be adopted in
Western countries in order to improve the pertussis control.
Discussion
Literature search
Data for this review were retrieved by searches of
Pubmed, references from relevant articles and open-
access websites of US Centers for Disease Control and
Prevention (CDC) and European Centre for Disease Pre-
vention and Control (ECDC). In order to verify the com-
pleteness of the PubMed database, we also performed
the same key word searches with other databases (Web
of Science, Embase, Pascal), but the results were virtually
overlapping with regard to the subjects of interest, or
supplied supplemental articles out of the scope of this re-
view. The search was limited to English-language publica-
tions involving humans. The search has been performed
in order to identify articles published between 1st Janury,
2002 and 1st March, 2013. In particular the search strategy
used in the PubMed database was the following: “pertussis
[Title] AND vaccine [Title]) AND (schedule [Title] OR
strategy [Title] OR booster [Title] OR (cost [Title] AND ef-
fectives [Title]) OR efficacy [Title] OR pregnancy [Title]
OR pregnant [Title] OR infants [Title] OR newborn [Title]
OR adolescents [Title] OR (health-care [Title] AND
worker [Title])) AND (hasabstract [text] AND “2003/02/
16” [PDat] : “2013/02/12” [PDat] AND “humans” [MeSH
Terms] AND English [lang])”. This search resulted in 132
articles which were reduced to 94 on the basis of titles
and abstracts.
Types of pertussis vaccines currently available in Western
countries
In developed countries whole cell pertussis vaccines
(wP) are not used anymore, due to the high rates of
reported adverse events. In the 1970s and 1980s acellular
pertussis (aP) vaccines were demonstrated to be effect-
ive, but less reactogenic than wP vaccines. As a conse-
quence aP are now adopted in Western countries [19].
No preparation containing pertussis antigens alone is li-
censed in the United States or Europe to date [20]. Sev-
eral pertussis vaccines are available combined with
diphtheria and tetanus toxoids plus, eventually hepatitis
B virus and/ or Haemophilus influenza type B and/or
poliovirus antigens (i.e. Infarix, InfarixHepB, Infarix-hexa,
Infarix-penta, Tetravac, Pentavac, Triacelluvax, Daptacel,
Pentacel). They may include three antigens from purified
Bartonella pertussis bacteria: pertussis toxin (PT), fila-
mentous hemagglutinin (FHA) and pertactin (PRN) (i.e.:
Infarix, Triacelluvax), or may be five-component vaccines
additionally containing fimbrial antigen 2 (Fim2) and fim-
brial antigen 3 (Fim3) (i.e. Daptacel, Pentacel) [21,22].
Currently, vaccines for the use in older subjects are also
available (i.e. Boostrix, Adacel) containing reduced quan-
tities (10-50%) of all antigens [20] to decrease the risk of
injection site reactions occurring more frequently after the
fifth dose of DTaP [23]. As an example, Boostrix is li-
censed for individuals from age 10 years onwards in the
United States and from age 4 years onwards in Europe
[24], while Adacel is approved in those aged 11–64 years
in the United States and in children (aged ≥ 4 years), ado-
lescents and adults in Europe [25].
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Figure 1 Age-specific incidence distribution of pertussis cases in European countries, 2005–2009 (from [13-17], modified).
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Efficacy and effectiveness data
Eight randomized controlled trials (RCTs) investigating
the efficacy of pertussis vaccines have been retrieved
(Table 1) [19,26,27]. Among these latter, 6 RCTs, overall
including more than 46,000 participants, have been pre-
viously analysed in a Cochrane systematic review [19],
demonstrating that the efficacy of multi-component
(≥ three) aP vaccines is 84-85% in preventing typical
whooping cough and 71-78% in preventing mild pertussis
disease (Table 1) [9,19]. wP vaccines were found to be
more efficacious than aP vaccines in some studies [28,29]
but not in others [30]. Multi-component (three or five) aP
vaccines showed higher efficacy than one- and two-
component aP vaccines against both typical and mild per-
tussis disease, while data were insufficient to establish
whether there was a clinically significant difference be-
tween three- and five-component aP vaccines [19]. Among
the remaining two RCTs, not included in the Cochrane re-
view, one study included about 83,000 children followed
up for three years and the reported efficacy was 72.3% for
the three component DTaP vaccine, 84.7% for the five
component DTaP vaccine, and 89.1% for DTwP vaccine
[26]. In another RCT, after a 2.5 year follow-up, efficacy of
a three-component aP vaccine was 92% (95% CI: 32-99%)
in 2,781 healthy subjects aged 15–65 years [27].
Besides efficacy data reported in RCTs, a lot of informa-
tion is available regarding vaccine effectiveness. In a US
study, including more than 1,000 children, aged 6 months
to 5 years, the estimated DTaP effectiveness was 83.6% for
1–2 doses, 95.0% for three doses and 97.7% for 4 or more
doses [31]. In a cross-sectional study conducted in
272,000 Australian adolescents (12–19 years) with a
three-component Tdap showed a vaccine effectiveness of
78.0% (95% CI: 60.7-87.6) [32].
Waning protection over years after aP vaccine has
been reported, but data largely differ across studies.
Laugauer and colleagues observed an effectiveness of
92% (95% CI: 84–9) for DTwP and 89% (95% CI: 79–94)
for DTaP at 6 years follow up [33]. In an Italian un-
blinded prospective study including 9,554 children, ef-
fectiveness was 78-81% depending on the vaccine type
during the first 6 years of life [22]. In a 1998–2009 UK
study, vaccine effectiveness declined from 97.6% among
infants 6–11 months of age to 83.7% among children
12–16 years of age (95% CI 69.5%–90.8%; p < 0.001)
[34]. In another UK observational study, however, effect-
iveness declined to 52% in the fifth year after vaccination
and to 46% in the seventh year after vaccination [35]. In
a recent report from the 2010 California pertussis out-
break including about 170 paediatric cases, the reported
vaccine effectiveness for a primary series and booster
doses at 12–18 months and 4–6 years of age was 41%
for children aged 2–7 years, but only 24% for children
aged 8–12 years, suggesting waning immunity over time
[36]. In interpreting such results it should be considered
that in some circumstances small coverage variations
could markedly change effectiveness observed. For ex-
ample, in the Campbell’ s study, effectiveness for patients
aged 10–16 years who received the DTwP vaccine under
the accelerated schedule would increase from 82% to
90% if coverage increased by one per cent, from 97.7%
to 98.7% [34].
Pertussis vaccination schedules currently adopted in
Western countries
Different vaccine strategies currently adopted in Western
countries have been summarized in Table 2 [7,37,38]. The
primary immunization series usually consists of three con-
secutive doses during the first year of life, followed by a
fourth dose in the second year of life and a fifth dose in
preschool age [7]. Regarding booster schedules in adoles-
cents, adults, including pregnant women and health
care providers, recommendations vary considerably, as
reported in Table 2.
Possible implementation strategies to be adopted in
Western countries
Vaccination of women during pregnancy
Several countries, including US and UK, currently rec-
ommend Tdpa administration in pregnant women
(Table 2) [39]. Safety data on Tdap vaccination in preg-
nant women are limited, however existing Tdap data
from the CDC, US Food and Drug Administration and
the pharmaceutical pregnancy registries do not indicate
a safety signal [40]. A recent US survey based on Vac-
cine Adverse Event Reporting System (VAERS) data, in-
cluding 2 reports of Tdap administered to pregnant
women, did not identify any concerning patterns in ma-
ternal, infant, or fetal outcomes [41]. Previous studies
have shown that the levels of pertussis antibodies are so
low in unimmunized or incompletely immunized mothers
that they will be undetectable in their infants’ blood within
2 months of age [42]. Efficient transplacental antibody
transfer and significantly higher titers have been found in
1-month-old infants, born after a maternal booster vaccin-
ation, compared with siblings born before the maternal
booster (Figure 2) [43,44]. A recent report assessed paired
maternal and umbilical cord sera collected from 52
women immunized with Tdap during pregnancy com-
pared with 52 women who were not. The data indicated
that newborns born to mothers who received Tdap during
pregnancy had significantly higher antibody titers to diph-
theria anti-toxin (p < 0.001), tetanus antitoxin (p = 0.004),
PT (p < 0.001), FHA (p = .0002), PRN (p < 0.0001) and
fimbriae type 2/3 (p < 0.001) when compared with new-
borns born to unimmunized mothers [40]. However, it is
uncertain whether this increase in antibodies can be con-
sidered clinically protective because no serological
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Table 1 Pertussis vaccine efficacy studies
Study (year) Country Type of analysis Included partecipans Dose schedule Type of vaccine Efficacy of vaccine
(95% CI)
AHGSPV 1988 USA Double bind parallel
group RCT
Age 5 to 11 months 2 doses (entry + 8 to 12 week later) aP: JNIH7 78% (57-88%)
aP: JNIH6 78% (58-89%)
Trollfors 1995 Sweden Double bind parallel
group \ RCT
Full term, healthy infants 3 doses (3, 5, 12 months) DTaP: Amvax 71% (63-78%)
Greco 1996 Italy Double bind parallel
group RCT
Age 6 to 12 weeks and
weight >3rd percentile
3 doses (6 to 12, 13 to 20, and 21
to 28 weeks)
DTaP: SKB 84% (76-89%)
DTaP: CB 84% (76-90%)
DTwP: CON 36% (13-50%)
Gustafsson 1996 Sweden Double bind parallel
group RCT
Age 2 to 3 months 3 doses (2, 4, 6 months) DTaP: SKB 59% (51-66%)
DTaP: CON 85% (81-89%)
DTwP: CON 48% (37-58%)
Simondon 1997 Senegal Parallel group RCT Age 2 months 3 doses (2, 4, 6 months) DTaP: Pasteur-Merieux 85% (66-93%)
DTwP: Pasteur-Merieux 96% (86-99%)
Olin 1997 Sweden RCT Age 2–3 months 3 doses (3, 5, 12 months or 2, 4,
6 months)
3-component DTaP 72%
5-component 85%
DTaP
DTwP 89%
PVSG 1998 Germany Parallel group RCT Age 2 to 4 months 4 doses (2 to 4, 4 to 6, 6 to 8, 12
to 14, and 15 to 18 months)
DTaP: Lederle/ Takeda 79% (72-85%)
DTwP: Lederle 84% (77-89%)
Ward 2006 USA Multicenter, double-
blind RCT
Age 15 to 65 years A single dose of a 3-component
aP vaccine
aP (PT, FHA, PRN) 92% (32-99%)
Abbreviations.
RCT: randomised controlled trial.
aP: acellular pertussis vaccine.
DTaP: diphtheria-tetanus-acellular pertussis vaccine.
DTwP: diphtheria-tetanus-whole-cell pertussis vaccine.
SKB: SmithKline Beecham.
CB: Chiron-Biocine.
CON: Connaught.
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correlate of protection is universally accepted for pertussis
[40]. Healy et al. have recently stressed the importance of
timing of maternal Tdap immunization [45]. Maternal
vaccination is ineffective during early weeks of gestation
because of the rapid decay of antibodies. It should be ad-
ministered during the third trimester to have maternal
pertussis antigen-specific IgG levels at their peak when
placental transport is the most efficient as possible. This
may protect the infant during the immediate postpartum
period when he is more vulnerable. Moreover,
immunization should be repeated in each subsequent
pregnancy [40,45].
Concern about the potential interference of maternal
pertussis antibodies with infant immune response to
Table 2 Current pertussis vaccination schedules in Western countries (modified from [7], [37], and [38])
Age at primary
series (months)
Childhood and adolescent boosters Adult boosters
Austria 3, 5 e 12 7-9 years and 13–15 years (only for
those who previously received a
Td booster)
Every 10 years
Belgium 2, 3 and 4 15 months, 5–7 years and 14–16 years Cocoon, health-care workers, adults in contact with
young children, day-care personnel
Finland 3, 5 and 12 4 years and 14–15 years Adults (who did not receive any pertussis vaccination
in the past 10 years), all health-care workers and cocoon
France 2, 3 and 4 16-18 months and 11–13 years Cocoon, young adults (booster at 26–28 years)
Germany 2, 3 and 4 11-14 months, 5–6 years and 9–17 years Every 10 years, cocoon
Italy 3, 5 and 11 5-6 years (and 11–15 years*) ..
Netherlands 2, 3 and 4 11 months and 4 years Cocoon, pregnant women
Poland 2, 4 and 6 16-18 months and 6 years ..
Switzerland 2, 4 and 6 15-24 months and 4–7 years; (11–15 years
catch-up)
Cocoon, young adults (booster at 25 years, 26–29 years
catch-up, and to adults of any age in personal or
professional contacts with infants≤ 6 months
Canada 2, 4 and 6 16-18 months, 4–6 years and 14–16 years Adults
United Kingdom 2, 3 and 4 3-5 years Cocoon, pregnant women
United States 2, 4 and 6 15-18 months, 4–6 years and
11–12 years
Cocoon, pregnant women, health-care workers, adults
(who did not receive any pertussis vaccination in the
past 10 years)
Australia 2, 4 and 6 4 years and 11–12 years Adults planning a pregnancy, cocoon (including grand-parent),
adults who work with young children (child-care workers and
health-care workers)
*Only in some regions.
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Figure 2 Geometric mean titers (GMT) for anti-pertussis toxin (PT) antibodies in women and children before and after a maternal
booster dose (from [44], modified).
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primary DTaP vaccination has been raised [44]. It seems
that the presence of circulating maternal antibodies can
inhibit active pertussis-specific antibody production in
the child. This blunting might reduce protection after first
months of life [18,39,46,47]. A 1995 study by Englund and
colleagues included 2,342 infants, who were randomized
to receive DTaP or DTP vaccines at 2, 4, and 6 months of
age. After DTP but not DTaP, higher levels of preexisting
antibody were associated with substantial (28% to 56%) re-
ductions in the subsequent antibody response to pertussis
toxin (PT). This finding suggests that the use of aP vac-
cines in adults, which could confer higher levels of anti-
body in women before pregnancy, would be unlikely to
adversely affect pertussis antibody responses after DTaP
among infants born to mothers with high antibody levels
[48]. Currently, two clinical trials are underway in Canada
and the United States to measure the response to routine
active immunization in the infants whose mothers re-
ceived Tdap vaccine during the third trimester of preg-
nancy [49,50].
Immunization of newborns
Immunization of newborns is another possible strategy
that has been investigated in some recent studies with
the rationale to provide protection in first months of life
when infants are more vulnerable. Halasa et al. analysed
the results of neonatal vaccination with DTaP vaccine in
50 infants between 2 to 14 days of age. The administra-
tion of an additional dose at birth was safe and well tol-
erated, but was associated with lower geometric mean
antibody concentration for toxin and pertactin at 6, 7,
and 18 months, for fimbrae at 6, 7, 17, and 18 months,
and for FHA at 18 months and lower geometric mean
antibody concentrations for diphtheria at 7 months [51].
In contrast, two other studies administering only aP at
birth, without diphtheria or tetanus toxoids, followed by
the DTaP series at 2, 4 and 6 months, reported an en-
hanced immune response against pertussis antigens at 2
and 8 months of age but lower levels of antibodies
against Haemophilus infuenzae type B and hepatitis B
[52,53]. However, at least 96% of subjects achieved anti-
body concentrations associated with seroprotection after
a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 -
months [54]. An Australian study assessed the immuno-
genicity and reactogenicity of two doses of aP vaccine,
one given at birth and the other one at 1 month. Data
suggest that aP vaccine administered before 2 months of
age induces significantly higher pertussis antibody titers
by 2 months of age without interference with responses
to routine active immunization [55].
The immaturity of the neonatal immune system and
the impact of passively transferred maternal antibodies
could explain the poor immune response in infants vac-
cinated at birth [43]. In infants DTaP vaccination may
trigger CD4+ T-lymphocytes functionally and phenotypic-
ally dissimilar from those of older children and adults [56].
Given these controversial reports, currently, immunization
with DTaP or aP vaccines is not recommended in
newborns. Additional clinical trials are needed in this
regard [18].
Cocooning strategy and postpartum mothers’ immunization
Cocooning strategy consists of providing indirect protec-
tion to infants who are too young to be immunized or
protected by vaccine through immunization of their par-
ents and other family members, caregivers and close con-
tacts [7,18]. Household members, particularly mothers, are
the source of transmission of pertussis to infants in up to
75% of cases [57]. However, casual community contacts
have been estimated to account for up to 34% of cases
[58]. There are very few empirical studies examining the
impact of cocooning strategy. In a US cross-sectional study
including more than 500 infants, immunizing only postpar-
tum mothers with Tdap did not reduce pertussis cases in
infants ≤6 months of age [59,60] suggesting that efforts
should be directed at immunizing all household and key
contacts of newborns, not just mothers. It should also be
considered that a maximum response to Tdap is not
achieved until 14 days after vaccination and in this gap
newborns are at risk of infection [61]. Despite the paucity
of data, economic and logistical difficulties, efforts to pro-
mote and effectively implement cocooning in Western
countries is continuing [18]. In 2006 the Advisory Com-
mittee on Immunization Practices (ACIP) recommended
routine administration of Tdap to all unvaccinated post-
partum mothers and in 2011 recommendations were ex-
tended including pregnant women and all people who have
or anticipate having close contact with an infant aged <12 -
months if they have not previously received it [39]. During
the 2010 Californian epidemic the cocoon strategy was
adopted together with other strategies such as adolescent
and adult boosters, resulting in an incidence decline from
23.4 to 2 cases/100,000 in one year [62]. Given the majority
of studies currently available are from the United States,
these results may not necessarily be applicable to other set-
tings. It is crucial that the countries where cocooning has
been implemented investigate its impact on pertussis inci-
dence to clarify its cost-effectiveness [63].
Vaccination of preschool children and adolescents
A preschool booster is usually included in the vaccination
schedules of many countries (Table 2). It contributes to in-
crease herd immunity and to reduce transmission to sus-
ceptible subjects [7]. A case–control study was conducted
in California from 2006 to 2011, involving children who
were vaccinated with all the five DTaP doses. The aim was
to establish the risk of pertussis in relation to the time
since the fifth DTaP dose. In this study protection against
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pertussis waned during the 5 years after the fifth dose of
vaccine and the risk of disease increased by 42% each year
[64]. Since the highest incidence of the disease is currently
reported among adolescents, a universal booster vaccin-
ation in this age class has been proposed. In one RCT effi-
cacy of Tdap in adolescents/adults was 92% [27], but the
reported effectiveness is lower. In 499 adolescents, during a
pertussis outbreak in a US school, vaccine effectiveness was
only 65.5% (95% CI: 35.8-91.3%) [65]. In Australia, Tdap
was administered from 2004 for 272,000 adolescents (aged
12–19 years) during a mass vaccination program. Vaccine
effectiveness was evaluated by the screening method and
it was 78.0%. The Australian experience supported the
positive impact of a large use of Tdap to rapidly control
pertussis in adolescents and suggested that a school-
based catch-up program followed by immunization of
school entrants might be the optimum strategy for the
implementation of adolescent coverage [32,66].
Since 2005, the ACIP has expanded the routine adoles-
cent vaccination schedule with the administration of one
Tdap dose. Therefore, from 2006 to 2009, Tdap coverage
among US adolescents increased from 10.8% to 55.6%
and then it reached 78.2% in 2011, but it still remains
below target levels [67]. Currently, the American Acad-
emy of Pediatrics recommends that adolescents 11 to
18 years of age should receive a single booster dose of
Tdap instead of tetanus and diphtheria toxoids (Td) vac-
cine (the preferred age is 11 to 12 years). Those who
have received Td but not Tdap are encouraged to re-
ceive a single dose of Tdap with a suggested interval of
at least 5 years between Td and Tdap to reduce the risk
of local and systemic reactions. The primary goal is to
protect immunized adolescents against pertussis. A sec-
ondary object is to reduce the reservoir of pertussis
within the population and prevent indirectly pertussis
cases in infants and young children, who have the
highest risk of complications [20]. Although a decreasing
trend of pertussis cases was observed in adolescents
after the introduction of Tdap vaccination, the average
incidence among infants younger than 1 year did not
change [68]. In Europe only few countries have intro-
duced booster doses for adolescents (eg, Austria,
Belgium, Finland, France, Germany and some Italian re-
gions) (Table 1) [7,69]. Data on effectiveness of adoles-
cent boosters in these countries are lacking [70].
Furthermore, at the Global Pertussis Initiative meeting
in Paris 2010, members stressed the need of efficacious
surveillance systems to evaluate the impact of dTap
booster on the disease incidence in adolescents [66,69].
Vaccination programs for adults
Reports from Europe and the United States highlight the
growing burden of pertussis in adult population [7]. Since
2005, the ACIP has recommended a Tdap vaccine booster
dose for those adults aged 19 through 64 years who have
not yet received a dose or have received their last dose of
Td ≥10 years earlier and they have not previously received
Tdap [71,72]. Despite these recommendations, Tdap cover-
age remained low in the US adults. In 2008 only 5.9% of
adults received a dose of Tdap and coverage among adults
with infant contact was estimated to be 5% [9].
In October 2010, ACIP recommended that unimmunized
adults aged ≥ 65 years shall be vaccinated with Tdap if in
close contact with an infant, and that other adults aged ≥
65 years may receive Tdap. In February 2012, ACIP
recommended Tdap vaccination for all adults aged ≥ 65 -
years [72]. Universal adult vaccination is an important strat-
egy to build up herd immunity and eradicate pertussis
infection [73]. In a randomized, multicenter, double-blind,
controlled trial called APERT (Acellular Pertussis Vaccine
Trial), 2781 healthy subjects between the ages of 15 and
65 years were recruited and received a single dose of either
an acellular pertussis vaccine or a hepatitis A vaccine (con-
trol). It was estimated that a single dose if Tdap gave a pro-
tective efficacy of 92% among adolescents and adults [27]. A
cost-benefit analysis showed that decennial adult booster
vaccination, although more expensive than adolescent
boosting, could prevent 0.9-4.7 million adult cases of pertus-
sis and save $1.3-6.4 billion in the US every 10 years [74].
In the past decade, the confusing recommendations
about Tdap immunization and the lack of precise guide-
lines resulted in underuse of the vaccine [75]. A universal
decennial Tdap booster program should be implemented
starting in preadolescents and continuing throughout
adulthood, including persons aged ≥65 years. The Consen-
sus on Pertussis Booster Vaccination in Europe group pro-
poses the administration of a single dose of Tdap instead
of dT in adults aged 18 years or older who have received
the preceding dT dose for more than 10 years. Epidemio-
logical studies are needed to define the appropriate inter-
val of time between the two boosters [7]. Until now only a
French study has assessed this problem. It concluted that
Tdap-IPV (inactivated poliovirus) may be administered to
adults as little as one month after Td-IPV without exacer-
bating post-vaccination side-effects [76]. Although Tdap
booster dose 10 years later the initial booster has been
proven to be equally immunogenic and well tolerated [77],
there is currently paucity of data regarding the incidence
of local reactions after repeated immunizations in adults.
Some authors advocated the production of a monovalent
acellular vaccine without diphtheria and tetanus toxoids
which could allow more frequent boosters in adults [78].
Immunization of health-care workers
Health-care workers are at a higher risk of infection than
the general population and, in turn, may be a substantial
source for susceptible individuals. As an example, in one
single-center study, 17 pertussis cases were identified,
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which exposed 355 unprotected health-care workers
[79]. Pertussis among health-care personnel has been
reported to be 1.7 times higher than among the general
population [72]. In 2006, the Health-care Infection Con-
trol Practises Advisory Committee supported the recom-
mendations of ACIP for the use of Tdap in health-care
providers. It was proposed that health-care personnel
who work in hospital or ambulatory care settings and
have direct contact with patients should receive a single
dose of Tdap as soon as feasible if they have not previ-
ously received Tdap; an interval as short as 2 years from
the last dose of Td was recommended. The aim was to
protect health-care workers against pertussis and to re-
duce transmission to patients. Priority had to be given to
those ones in frequent contact with pregnant women, in-
fants, children or immune compromised patients [71].
However, in 2008 Tdap vaccination coverage was only
15.9% among the United States health-care workers [9].
In some European countries (eg, France and Belgium),
Tdap boosters for health-care workers are recommended
(Table 2) [7]. In 2007, the French National Institute for
Health Surveillance analysed data about nosocomial in-
fections and community clusters of pertussis in France,
reported between 2000 and 2005. Almost half of the 67
reports analysed were coming from hospitals and health-
care workers were usually the first to be affected [80,81].
Studies are needed to evaluate the effectiveness of Tdap
immunization in preventing pertussis in health-care pro-
viders and in their contacts, and to establish the dur-
ation of protection [71].
Cost–effectiveness, cost-utility and economic impact
model studies
In a recent review Millier and colleagues identified 13
cost-effectiveness, cost-utility and economic impact
models regarding the impact of adolescent booster, one-
time adult booster, adult decennial boosters and/or co-
coon strategy. Adolescent booster was found to be a
cost-effective strategy compared with no booster vaccin-
ation in all the nine considered studies [82]. As an ex-
ample, Purdy et al. showed that immunizing adolescents
aged 10–19 years would be the most economical strategy
since it would prevent 0.7-1.8 million pertussis cases and
save $0.6-1.6 billion over a decade in US [74]. However,
in another recent review including 16 studies using a dy-
namic model, adolescent vaccination was found to be
cost effective, but not highly effective in protecting infants
too young to be vaccinated [83]. Similarly in another re-
cent study, using an age-structured compartmental deter-
ministic model, a single Tdap dose at age 11 years
significantly would reduce the incidence of the disease
within this age group, but would have a very low impact
in infants [84].
The conclusions concerning adult vaccination, alone
or in combination with adolescent vaccination, are also
contrasting. A US cost-benefit analysis concluded that,
although more expensive than adolescent boosting, de-
cennial adult booster vaccination could prevent 0.9-4.7
million adult cases of disease and save $1.3-6.4 billion
every 10 years [74]. In a recent study from Netherlands,
combining an adolescent booster dose at the age of 10 -
years (most cost-effective age for a single adolescent
booster dose) with an adult (18–30 years) booster dose
resulted in favourable incremental cost-effectiveness ra-
tios (ICERs) in terms of quality-adjusted life years
(QALYs) (<€10,000/QALY) and the every 10 year
booster dose resulted in an ICER of €16,900 per QALY
[85]. On the other hand, in a German study adult vac-
cination would be cost-saving only if the incidence were
higher than 200 per 100,000 and Lee et al. estimated
that only 1.4% of cases would be prevented and adult
booster strategy should not be adopted [82,86].
Available studies generally suggested the cost-effectiveness
of the cocoon strategy, despite some conflicting results. In a
Netherland study cocooning obtained by immunization of
both parents was the most expensive intervention to imple-
ment but also the most effective. The base-case analysis sug-
gested a reduction in the overall number of pertussis cases
in infants by 26% [87]. Coudeville et al. in an economic
evaluation including the dynamic population effects, con-
cluded that the cocoon strategy complemented by a single
booster dose was the most cost-effective one, and was asso-
ciated with a 80% reduction of pertussis costs [88]. Differ-
ently, in a study by Lee et al., postpartum vaccination was
found to be more costly than adolescent vaccination and
would provide fewer health benefits [82]. In a recent
Canadian study Skowronsky et al. suggest that parent
immunization is inefficient and expensive in areas
where disease incidence is low. In this setting the num-
ber needed to vaccinate should be at least 1 million to
prevent 1 infant death, approximately 100,000 to pre-
vent 1 infant ICU admission and more than 10,000 to
prevent 1 infant hospitalization [59,89]. In Australia,
Scuffham et al. reported an ICER of AUS$787,504 per
DALY (disability-adjusted life-year) avoided versus no
current schedule [90]. Parental vaccination would re-
duce pertussis cases, deaths and DALYs by 38.6%,
38.2%, and 38.3%, respectively. Nevertheless, it was not
cost-effective, and dominated by the at-birth vaccin-
ation strategy [82].
Regarding the vaccination of pregnant women, some
data are available supporting this strategy as cost-
effective [39,61]. In a recent US study immunization
during pregnancy was found to prevent a greater num-
ber of infant cases and deaths than postpartum one [91].
In a Netherland study the cost-effectiveness of cocoon-
ing and maternal vaccination were estimated to be
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similar, with ICERs of €4,600/QALY and €3,500/QALY,
respectively [87]. It should be considered that these
studies may be affected by abstract assumptions about
unreported cases, real incidence, other epidemiological
data, costs associated with mild disease and herd im-
munity effects [82].
New possible vaccines
Currently available vaccines have clearly major limits
and new vaccines are under developing in order to bet-
ter control this disease. New vaccines could include add-
itional protective antigens. Possible candidates include
the adenylate cyclase toxin, the autotransporte BrkA,
and an antigen induced by iron starvation, named IRP1-
3 [21]. Another field of research is directed to develop a
vaccine promoting the skewing of a predominant Th1
and Th17 immune response, which is the most effective
[75]. Garlapati et al. studied a novel microparticle based
vaccine formulation consisting of pertussis toxoid (PTd),
polyphosphazene (PCEP), CpG ODN 10101 and syn-
thetic cationic innate defence regulator peptide 1002
(IDR) against Bordetella pertussis in mice. Even if pro-
tection against pertussis is mediated by both humoral
and cell-mediated immunity, several studies demon-
strated that the Th1 and Th17 cell-mediated immune re-
sponses to initial doses of pertussis vaccines correlate
better with long-term immunity than antibody levels. In-
vestigators concluded that immunization with PTd en-
capsulated into microparticles and adjuvanted with CpG
ODN and IDR induced a strong shift towards Th1/Th17
responses, with long-term immunity [75,92].
Another future objective is the development of a more
immunogenic and efficacious vaccine using different
immunization route and/or live attenuated vaccines [75].
Some researchers obtained a highly attenuated Bordetella
pertussis strain that was able to colonize the mouse re-
spiratory tract and to provide full protection after a single
intranasal administration. These results provided hope for
the development of novel vaccination strategies that could
be used in the very young children, even at birth [93]. The
intranasal route mimics the natural route of infection,
stimulating mucosal immunity in addition to the systemic
immune response. It could induce longer term protec-
tion than that offered by the currently marketed aP
vaccines [94].
However it should be considered that he current DTaP
vaccines are the basis of the infant immunization series and
to replace them with new vaccines will require testing of all
the other antigens. Thus, their use in the clinical practice
could be difficult to be achieved in a short time period [21].
Summary
Pertussis outbreaks continue to be reported in Western
countries with high vaccination coverage. Despite the
relevant efforts to protect all the groups at risk and
interrupt the transmission of infection, the introduction
of new strategies, including maternal vaccination, co-
coon strategy, vaccinations in adolescents and adults
have been suggested pursue this goal. All the strategies
we have described focus on two of the several reasons
for the on-going pertussis outbreaks, the inadequate
levels of pertussis vaccination coverage in the population
and the waning of vaccine-induced immunity in adoles-
cents and adults over time. Other important causes must
be considered: the loss of vaccine efficacy due to the
emergence of new Bordetella pertussis strains and the
possible skewing of pertussis immune responses in chil-
dren due to use of the aP vaccine in early childhood.
Cost-effectiveness studies provide some contrasting data,
mainly supporting both maternal vaccination and co-
cooning. Adolescent and/or adult vaccination seems to
be cost-effective, however data from observational stud-
ies suggest that this vaccination strategy, used alone,
leads to a reduced pertussis burden, globally, but does
not affect the disease incidence in infants. Moreover
substantial logistical and economic difficulties have to be
overcome to vaccinate the largest number of individuals.
Policymakers should invest more resources in the educa-
tion of public health providers and of the population
about the benefits of vaccination. The development of
new highly immunogenic and efficacious pertussis vac-
cines continues to be a primary objective for the control
of pertussis.
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